Laropiprant/Nicotinic Acid

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameLaropiprant/Nicotinic Acid
Drug Alias Name烟酸/拉罗匹仑Nicotinic Acid/LaropiprantLaropiprant and Nicotinic AcidNicotinic Acid and LaropiprantTredaptive +[8] 
ClassificationSmall molecules
Mechanisms of ActionProstaglandin D2 receptor antagonistsHydroxycarboxylic acid receptor 2 agonistsHM74 nicotinic acid GPCR agonists
TargetsProstaglandin D2 receptorHydroxycarboxylic acid receptor 2HM74 nicotinic acid GPCR
Therapy Area/IndicationsHeterozygous familial hypercholesterolemiaFlushingHypercholesterolemia +[12] 
Global Approved IndicationsDyslipidemias
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2008/07/02
Country/TerritoryUnited KingdomEU
CombinationsYes LaropiprantNicotinic Acid
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of OxfordMerck Sharp & Dohme LtdMerck Sharp & Dohme LLC
Active IndicationsN/A
Inactive IndicationsHeterozygous familial hypercholesterolemiaFlushingHypercholesterolemia +[12] 

Other Information

ATC CodeC10AD52
Related LinksN/A